Oxford Biomedica plc (LON:OXB) Given Average Recommendation of “Moderate Buy” by Analysts

Oxford Biomedica plc (LON:OXB) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is GBX 687.

Several research firms have issued reports on OXB. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 950 target price on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Jefferies Financial Group began coverage on shares of Oxford Biomedica in a research note on Monday, March 23rd. They issued a “buy” rating and a GBX 827 target price on the stock.

Oxford Biomedica Stock Performance

LON OXB opened at GBX 628 on Monday. Oxford Biomedica has a 1 year low of GBX 305.50 and a 1 year high of GBX 952. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67. The stock has a market capitalization of £759.37 million, a PE ratio of -23.33 and a beta of 1.10. The company’s 50 day simple moving average is GBX 604.98 and its two-hundred day simple moving average is GBX 663.95.

Oxford Biomedica (LON:OXB) last posted its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. Analysts predict that Oxford Biomedica will post -31.0799998 earnings per share for the current fiscal year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.